Tiziana Life Sciences doses first patients in Phase 2a intranasal foralumab ALS trial
TLSA•Tiziana Life Sciences dosed the first three participants in a Phase 2a trial of intranasal foralumab for ALS, which aims to enroll 44 early-stage patients and assess safety and biomarkers over 24 weeks.
1. Trial begins dosing
Tiziana Life Sciences dosed the first three participants in its Phase 2a trial of intranasal foralumab for ALS. The study targets 44 early-stage patients, with 3:1 randomization between active drug and placebo, and a 24-week treatment plan. Its primary measure is tolerability, with secondary measures aimed at assessing immune modulation; no results have been presented.
